Following footsteps of chart-topping Chinese counterparts, Alphamab Oncology files IPO at HKEX
Less than two months after raising $60 million — its second venture round in a decade — Alphamab is making the hop for the public markets.
In its IPO filing with the Hong Kong stock exchange, the Suzhou-based company describes in more detail a game plan it sketched out in May: Beat down a direct path to market for its two lead bispecifics by running multiple parallel clinical programs, while prepping for the potential commercialization of its subcutaneous PD-L1 and advancing another CTLA-4-based immunosuppressant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.